Bills / H.R. 10770
H.R. 10770
340B Rebate Model Delay Act
In plain English
340B Rebate Model Delay Act This bill temporarily limits the use of rebates for prescription drugs under the 340B program and delays the implementation of the 340B Rebate Model Pilot Program. Under current law, the 340B program generally limits the maximum price drug manufacturers participating in Medicaid or Medicare can charge eligible health care organizations for covered outpatient drugs. Beginning on January 1, 2027, and ending on December 31, 2028, the bill prohibits drug manufacturers from entering agreements with 340B organizations that require the organization to pay more than the allowable ceiling price for a covered outpatient drug at the time of purchase and subsequently receive a rebate to comply with the maximum price requirements. The bill also delays until January 1, 2029, the implementation of the 340B Rebate Model Pilot Program. The pilot program allows approved drug manufacturers to charge 340B organizations full price for certain high-impact drugs and provide a rebate that reduces the amount paid to the allowable ceiling price after the drug is dispensed. Under the pilot program, the rebates are verified and issued on a claim-by-claim basis.
Congressional Research Service summary from Congress.gov (not yet simplified).
Sponsor and status
Loading from Congress.gov…
How South Carolina voted
No recorded roll-call vote on this bill yet. Most bills never get one.
Who lobbied
Lobbying reports name the bills a client worked on. They don't say which side anyone took.
No lobbying reported on this bill in the reports we have loaded (January 2025 through September 2026). Lobbyists report each quarter, about 20 days after it ends, so any lobbying since October 2026 will be added once those reports are filed.